ImmuPharma plc (LON:IMM – Get Free Report) shares dropped 2.9% on Wednesday . The company traded as low as GBX 2.82 ($0.03) and last traded at GBX 2.99 ($0.04). Approximately 2,807,457 shares were traded during trading, a decline of 86% from the average daily volume of 19,594,438 shares. The stock had previously closed at GBX 3.08 ($0.04).
ImmuPharma Price Performance
The stock has a market capitalization of £16.57 million, a P/E ratio of -397.90 and a beta of 1.53. The company’s 50-day simple moving average is GBX 1.71 and its 200-day simple moving average is GBX 1.72.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- What Are Trending Stocks? Trending Stocks Explained
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- What Are the FAANG Stocks and Are They Good Investments?
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
